StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
359090.KQ$547.00-3.87%
Fair $547.00+0.0%

359090.KQ

C&R Research Inc.

Healthcare / Health Information ServicesKOSDAQ

$547.00

-22.00 (-3.87%)

Fairly Valued+0.0%Fair Value $547.00Fund rank 29/100 · Data gapFallback financials|
SA 36/D
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 22%

FCF escenarios

weak_data · normalized FCF $2.0B · quality 48.7/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

36/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 359090.KQLocal privado en este navegador · C&R Research Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$31.4B

P/E

12.2x

↓

EV/EBITDA

12.6x

↑

ROE

5.2%

↑

Gross Margin

100.0%

↑

Debt/Equity

0.15

↓
52-Week Range$547
$510$1178

TradingView lightweight chart

359090.KQ price, volumen y niveles de valoración

Último $547.00Periodo -78.5%
Fair value: $547.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+10.3%

FCF CAGR

—

FCF margin

-5.2%

FCF / Net income

-1.30x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $64.98B · net income $2.59B · FCF $-3.36B

2022-FY → 2025-FY

Gross margin

100.0%+0.0% pts

Operating margin

2.1%-7.8% pts

Net margin

4.0%-4.1% pts

FCF margin

-5.2%-7.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$64.98B$64.98B$59.69B$55.10B$48.47B
Net Income$2.59B$2.59B$3.84B$5.56B$3.93B
EBITDA$2.36B$2.36B$5.15B$7.33B$5.21B
EPS45.0045.0068.00100.0073.00
Gross Margin100.0%100.0%100.0%100.0%100.0%
Operating Margin2.1%2.1%6.1%11.3%9.9%
Net Margin4.0%4.0%6.4%10.1%8.1%
Balance Sheet
Debt/Equity0.150.150.120.150.22
Current Ratio1.001.00———
Cash Flow
Free Cash Flow$-3.36B$-3.36B$1.97B$3.29B$1.26B
Returns
ROE5.2%5.2%8.2%13.2%10.9%
Valuation
P/E12.1612.1617.6212.3615.62
EV/EBITDA12.6012.6011.849.2812.01
P/B0.640.641.441.631.70
Growth & Yield
Revenue Growth8.9%8.9%8.3%13.7%—
EPS Growth-33.8%-33.8%-32.0%37.0%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

2.6%

fácil

EPS terminal req.

$48.54

Spread vs growth

-36.4%

5Y implied EPS CAGR

5.5%

razonable

EPS terminal req.

$58.73

Spread vs growth

-39.3%

10Y implied EPS CAGR

7.7%

razonable

EPS terminal req.

$94.59

Spread vs growth

-41.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -44.8%

Total return

-44.8%

Start / end P/E

15.1x → 12.2x

EPS bridge

68.00 → 45.00

Residual

+6.5%

EPS growth-33.8%
Multiple rerating-19.4%
Dividend+1.8%
Residual / FX / buybacks / cross-term+6.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.